AVEO Pharmaceuticals — Investor Presentation (June 2016)
36 slides from AVEO Pharmaceuticals's investor presentation, Jun 15, 2016
Slide 1: AVEO Overview June 2016
AVEO Overview June 2016 Exhibit 99.1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation are forward-looking statements. The words “anticipate,” “believe,” “estimate,”
Slide 3: Retained North American Rights for Oncology Portfolio While Leveraging Partnerships
Retained North American Rights for Oncology Portfolio While Leveraging Partnerships to Advance Our Pipeline AV-380 GDF15 MAb Tivozanib VEGF 123 TKI (Oncology Indications) AV-203 ERBB3 MAb Ficlatuzumab HGF MAb Value Creation Strategy Leverage partner resources to advance development, retain significa
Slide 4: Partnerships Provide Significant Downstream Value Potential, Support for North American Strategy
Partnerships Provide Significant Downstream Value Potential, Support for North American Strategy Tivozanib EU, Other December 2015 Tivozanib Ocular November 2014 AV-380 August 2015 Ficlatuzumab April 2014 Potential for ~$1 Billion in partnership payments plus meaningful royalties AV-203 March 2016
Slide 5: Multiple Opportunities for Value Creation
TIVO-1 (1st Line RCC) * Ocular Serum Proteomic Biomarker NSCLC NRG-1 Biomarker Solid Tumors Cachexia U.S. Phase 3 Registration Study in RCC PD-1 RCC PAH Multiple Opportunities for Value Creation *Filed in EU by EUSA FEB 29, 2016, validated MAR 23, 2016 Seeking Partnership
Slide 6: Tivozanib
Tivozanib A potent, selective, long half-life inhibitor of vascular endothelial growth factor (VEGF) 1, 2 and 3 receptors
Slide 7: Tivozanib: VEGFR 1, 2 and 3 Tyrosine Kinase Inhibitor
Tivozanib: VEGFR 1, 2 and 3 Tyrosine Kinase Inhibitor Potent, selective inhibitor of VEGFRs 1, 2 and 3 with a long half-life that is designed to optimize blockade while minimizing off-target toxicities1,2 1. Nakamura K et al. Cancer Res 2006;66:9134–9142. 2. Eskens FA et al. Clin Cancer Res 2011;17:
Slide 8: Large and Growing RCC Opportunity
Large and Growing RCC Opportunity ~$1.5 Billion ~$1.0 Billion Market opportunity currently ~$2.5 billion in Europe and North America* Future market needs: Improved tolerability Increased efficacy through combinations with immunotherapy * Total RCC market includes all stages of disease and treatment
Slide 9: Tivozanib RCC Potential development and registration scenarios
Tivozanib RCC Potential development and registration scenarios MAA Review TIVO-3 – Tivo v. Sorafenib US Approval Decision EU Approval Decision NDA Review 2016 2017 2018 2019 2020 Ph 2 expansion or Ph 3 Trial of Tivo + PD-1 Ph 1/2 Tivo + PD-1 Potential NDA Filing 2H 2018 PFS Data/OS Trend Estimated 1
Slide 10: Tivozanib RCC Front-line Setting
Tivozanib RCC Front-line Setting
Slide 11: TIVO-1: Proven Activity in 1st line RCC
Phase 3 TIVO-1: Proven Activity in 1st line RCC 517 patient, global, randomized Phase 3 in 1st line RCC First H2H RCC pivotal to meet primary PFS endpoint of superiority vs VEGF TKI OS confounded by crossover; NDA not approved; FDA requested additional study Demonstrated favorable tolerability profi
Slide 12: Comparable OS Despite Limited Subsequent Therapy
Comparable OS Despite Limited Subsequent Therapy
Slide 13: Support for Tivozanib MAA Filing for RCC: Impact of Next-Line Therapy on OS
Support for Tivozanib MAA Filing for RCC TIVO-1: Impact of Next-Line Therapy on OS * EU includes Bulgaria, Czech Republic, France, UK, Hungary, Italy, Poland, Romania (countries with patients enrolled in Study 301) ** EU5 includes UK, Italy, and France (EU5 countries with patients enrolled in Study
Slide 14: EUSA Pharma Oncology Licensing Agreement
EUSA Pharma Oncology Licensing Agreement EU filing 2/29/16, validated 3/23/16 >$396M in Upfront and Potential Milestones $16M potential 2016/17 milestones* Tiered royalties from low double digits to mid twenties Milestone and royalty payments subject to the successful development or commercializatio
Slide 15: Favorable Tolerability vs. Approved TKIs in RCC
Favorable Tolerability vs. Approved TKIs in RCC 1. AVEO Data on file; 2. INLYTA prescribing information v.01.2012; 3.Votrient prescribing information revised 01.2012; 4. Sutent prescribing information revised 05.2011; 5. Cabozantinib METEOR Trial NEJM 9.2015; 6. Lenvatinib USPI Dose Reductions: Cabo
Slide 16: Tivozanib is Well Tolerated, Potential Preferred TKI for PD1 Combination Therapy
Tivozanib is Well Tolerated, and Has the Potential to Become the Preferred TKI for PD1 Combination Therapy Single Agent Toxicity All grade (Gr 3/4) Sutent1 (n=548) Votrient1 (n=554) Inlyta3 (n=359) Nexavar4 (n=257) Cometriq2 (n=331) Lenvatinib5 + Everolimus Tivozanib4 (n=259) Hypertension 30% (15%)
Slide 17: Top Three Toxicities Relevant to Patients with Advanced RCC
Top Three Toxicities Relevant to Patients with Advanced RCC* *Wong M, et al. J Med Econ. 2012;28:1-10. Additional months of PFS benefit patients require to accept adverse events >50% of pts on Nexavar <15% for Tivozanib >60% of pts on Sutent <20% for Tivozanib >50% of pts on Pazopanib, Axitinib and
Slide 18: Tivozanib North American Registration Strategy
Tivozanib North American Registration Strategy
Slide 19: TIVO-3: Phase 3 Study Design in Recurrent/Metastatic RCC
TIVO-3: Phase 3 Study Design in Recurrent/Metastatic RCC to Confirm TIVO-1 N = ~322 F Recurrent/metastatic RCC Failed at least two prior regimens including VEGFR-TKI (not sorafenib) ECOG PS 0 or 1 RANDOMIZE 1:1 tivozanib sorafenib 1O: PFS 2O: OS, ORR, DoR, Safety and tolerability for ITT & Pre-Speci
Slide 20: Tivozanib Efficacy in VEGF TKI Refractory Setting
Tivozanib Efficacy in VEGF TKI Refractory Setting * n= 389; investigator assessed PFS; independent PFS = 4.8 mo vs. 3.4 mo, HR = 0.741 (p=0.011) **investigator assessed PFS ^Cabozantanib USPI Motzer et al Lancet Oncol 2013; 14: 552–62 Motzer et al Lancet Oncol 2014 Hutson et al ASCO 2015 Motzer ESMO
Slide 21: Tivozanib PD-1 Combination Setting
Tivozanib PD-1 Combination Setting
Slide 22: Rationale for combining VEGF + PD-(L)1 inhibitors
Rationale for combining VEGF + PD-(L)1 inhibitors Gunturi, McDermoot Current Treatment Options in Oncology 2014 Pilmack International Kidney Cancer Symposium 2014
Slide 23: Tivozanib Properties Favorable for PD-1 Combination
Tivozanib Properties Favorable for PD-1 Combination Pawlowski N et al. AACR 2013. Poster 3971.
Slide 24: Early Data for Axitinib + Pembrolizumab: Promising Efficacy, Challenging Toxicity
Early Data for the Combination of Axitinib + Pembrolizumab: Demonstrated Promising Efficacy, Challenging Toxicity Atkins et al, SITC 2015 *Selected AEs include all with Grade 3/4 Three DLTs reported: transient ischemic attack (TIA; n=1) and < 75% of planned axitinib dose received due to treatment-re
Slide 25: Toxicity in Select TKI Combinations with PD-1s
Toxicity in Select TKI Combinations with PD-1s Courtesy of Dr. S. Pal, ASCO GU 2015
Slide 26: Comparison of Liver AEs in TKIs
Axitinib Tivozanib Axitinib Tivozanib Comparison of Liver AEs in TKIs Liver AEs are significantly higher for sutent, pazopanib and axitinib, compared to tivozanib When TKIs and PD1s are combined, the increase in Grade 3/4 AEs is more than additive When combined with PD1, Grade 1/2 AEs appear to be a
Slide 27: Robust Pipeline Development Funded by Partnerships
Robust Pipeline Development Funded by Partnerships
Slide 28: Tivozanib: Non-Oncology Exclusive License Agreement
Tivozanib: Non-Oncology Exclusive License Agreement >$105M total in upfront and potential option & milestone payments Potential for $10M in 2016 Tiered, double digit royalties, up to the mid-teens, on net sales* Figures from Ophthotech R&D Investor Day Dec 3, 2015 Option, milestone and royalty payme
Slide 29: Advancing Robust Pipeline Through Partnership
Advancing Robust Pipeline Through Partnership Milestone and royalty payments subject to the successful development and/or commercialization of the product *A percentage of proceeds will be shared with SVH, including of $1.5 million of upfront AV-380 (GDF-15 inhibitor MAb) Indication: Cachexia Incide
Slide 30: AV-353: First-in-Class Opportunity in Pulmonary Arterial Hypertension
AV-353: 1st-in-class opportunity to address major unmet need in Pulmonary arterial hypertension (PAH) as first drug with disease modifying properties Binding specificity to Notch 3 reduces risks of pan-Notch toxicities that have hampered competitors Large Market Opportunity 2014 sales of $3.45B à 20
Slide 31: Financials & Summary
Financials & Summary
Slide 32: Financial Highlights
Financial Highlights Cash and anticipated operational milestones to fully fund North American tivozanib development strategy to topline data $24M in cash and investments as of 1Q 2016 $17M equity financing completed 2Q 2016 Amended debt agreement for additional $5M, access to another $5M tranche and
Slide 33: Significant Progress During 2015 and 2016
Significant Progress During 2015 and 2016 Tivozanib Initiation of 3rd line confirmatory RCC Phase 3 study Filing and acceptance of filings in EU Partnership in EU ASCO presentation of refractory RCC data Presentation of encouraging CRC data Pipeline AV-380 partnership and option exercise AV-203 part
Slide 34: Potential Corporate Milestones
Potential Corporate Milestones Tivozanib Regulatory decision in EU (1Q17) Other geographic partnerships Initiation of PD1 combination study Proof of concept in AMD and option exercise (2016/17) TIVO-3 PFS data/OS trend (1Q18) Potential NDA submission (2H18) Pipeline (2016/17) Partnership for AV-353
Slide 35: AVEO Oncology Highlights
AVEO Oncology Highlights Retained significant North American (N.A.) rights for all oncology therapeutic assets Executing on potential N.A. registration strategies for Tivozanib Enrolling Ph 3 refractory RCC study (TIVO-3) to support 1st & 3rd line indications Anticipated PD1 combination study in RCC
Slide 36: AVEO Overview June 2016
AVEO Overview June 2016
AVEO Pharmaceuticals — Investor Presentation (June 2016) on 6ix